The Food and Drug Administration (FDA or Agency) is announcing the availability of a document entitled ``Recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus: Guidance for Industry.'' The guidance document provides blood establishments that collect blood and blood components with recommendations for donor screening, donor deferral, and product management to reduce the risk of transfusion- transmitted Zika virus (ZIKV). The guidance applies to the collection of Whole Blood and blood components intended for transfusion. The guidance does not apply to the collection of Source Plasma.
Document
Recommendations for Donor Screening, Deferral, and Product Management To Reduce the Risk of Transfusion-Transmission of Zika Virus; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a document entitled ``Recommendations for Donor Screening, Deferral, and Product Management to...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
81 FR 8504
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Recommendations for Donor Screening, Deferral, and Product Management To Reduce the Risk of Transfusion-Transmission of Zika Virus; Guidance for Industry; Availability,” thefederalregister.org (February 19, 2016), https://thefederalregister.org/documents/2016-03393/recommendations-for-donor-screening-deferral-and-product-management-to-reduce-the-risk-of-transfusion-transmission-of-zi.